With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities is only natural. | With GSK kicking its R&D engine into high gear in ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of ...

Source: CBRE Insights report Job cuts When it comes to employment, the larger effects of funding cuts and tariffs will take time to materialize, Ginther says.

The investment is highlighted by a state-of-the-art API facility in Virginia and expansions across multiple states.